Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Price action
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by Gilly123on Mar 25, 2021 9:28am
179 Views
Post# 32874222

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price action

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price actionMy spelling is not great. What does this have to do with investing?

I started with 4k in my account in 2012 and without adding any additional funds it is now 95k. I am admittedly not an expert, and do have a lot to learn. I am satisfied with these returns.

My preference is to swing trade over weeks or months. MMEd is going to be a good investment for a lot of people given some time. Still looking at my $2.00 target (although Ill set the buy order closer to 2.2). If you havnt noticed we are inching closer to it every day.

Keep your petty insults to yourself Teddy TeaBagger, and add something useful to the message board
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities